ImmunologybioRxivPreprint
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
D. A. Knorr, R. Leidner, S. Jensen…·J. Ravetch
This paper identifies FcyRIIB as an inhibitory Fc receptor limiting Treg depletion by anti-CTLA-4 antibodies and shows Fc engineering can enhance their efficacy.